Menu
Search
|

Menu

Close
X

Forward Pharma A/S FWP.OQ (NASDAQ Stock Exchange Global Select Market)

3.18 USD
-0.07 (-2.15%)
As of Feb 16
chart
Previous Close 3.25
Open 3.22
Volume 7,975
3m Avg Volume 14,052
Today’s High 3.22
Today’s Low 3.15
52 Week High 30.46
52 Week Low 3.00
Shares Outstanding (mil) 23.59
Market Capitalization (mil) 148.63
Forward P/E 0.84
Dividend (Yield %) 23.12 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
1,250
FY16
0
FY15
0
EPS (USD)
FY17
1.914
FY16
-0.711
FY15
-0.790
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
0.84
34.43
Price to Sales (TTM)
vs sector
0.12
8.57
Price to Book (MRQ)
vs sector
0.06
5.14
Price to Cash Flow (TTM)
vs sector
0.16
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
141.31
13.54
Return on Equity (TTM)
vs sector
141.32
14.80

EXECUTIVE LEADERSHIP

Claus Svendsen
Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Joel Sendek
Chief Financial Officer, Since 2014
Salary: --
Bonus: --
Thomas Carbone
Vice President - Finance, Controller, Since 2014
Salary: --
Bonus: --
Florian Schonharting
Chairman of the Board, Since 2005
Salary: --
Bonus: --
Torsten Goesch
Director, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Oestergade 24A, 1, Copenhagen K
KOEBENHAVN K     1100

Phone:

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company's clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis. The Company's DMF formulation, FP187, employs over two methods, which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels, which, in turn, controls DMF's side effects. The Company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.

SPONSORED STORIES